Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) shares extended gains and rose another 6.63% after surging over 60% since Monday. On Monday, the company expanded its management team, laboratory capacities, and commercial operations in preparation for an increase in sales. Moreover, Yesterday Aegis initiated coverage on shares of Rosetta Genomics in a research note released today and the firm issued a buy rating and a $16.00 price target on the stock.
Can ROSG Continue To Move Higher? Find Out here
Aware, Inc. (NASDAQ:AWRE) stock gained 4.06% to $5.90 after the company announced that it has signed an agreement for the sale of selected patents and patent applications to TQ Delta, LLC for USD16,000,000, subject to customary closing conditions and any required regulatory approvals. The patents and patent applications relate to DSL technology.
BP plc (ADR) (NYSE:BP) stock fell 0.73% to $41.93 after the company yesterday said that it has fixed a problem at its Whiting, Ind. refinery that led to a three-state fuel recall but has temporarily halted selling premium and midgrade gasoline in the Chicago area.
Additionally, the company expects to start next year deep-sea drilling work off the coast of Libya, as the U.K. oil giant resumes it $2 billion exploration program halted by the rebel overthrow of Col. Moammar Gadhafi's regime last year.
MER Telemanagement Solutions Ltd. (NASDAQ:MTSL) shares climbed 15.45% to $3.81 in the early hour. The company announced that TMC, a global, integrated media company, has named TEM Suite as a recipient of a 2011 Communications Solutions Product of the Year Award. MTS TEM Suite is a fully integrated TEM and EMM (Enterprise Mobility Management) cloud suite and managed services solution that provides enterprises the ability to comprehensively manage their wireline and wireless communications environments.
Can MTSL Continue To Move Higher? Find Out here
Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) shares jumped 9.17% to $1.19 in the morning hour. The 52 week trading range for the company is $0.48 - $4.75. The company early this month ended the second quarter with $142.2 million in cash and short-term securities. Savient's revenues largely come from its recently approved gout drug Krystexxa, which had sales of $4 million for the second quarter.